Immunome (IMNM) Current Deferred Revenue (2023 - 2025)

Immunome (IMNM) has 3 years of Current Deferred Revenue data on file, last reported at $4.0 million in Q1 2025.

• Quarterly Current Deferred Revenue fell 68.5% year-over-year to $4.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $4.0 million (down 68.5% YoY) and the FY2024 annual result came in at $6.9 million, down 56.57% from the prior year.
• Current Deferred Revenue slipped to $4.0 million in Q1 2025, from $6.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $27.6 million in Q1 2023 to a low of $4.0 million in Q1 2025.
• A 3-year average of $14.4 million and a median of $12.7 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue slumped 42.92% — and 2025, when it slumped 68.5%.
• Tracing IMNM's Current Deferred Revenue over 3 years: stood at $16.0 million in 2023, then plunged by 56.57% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
• The last three Current Deferred Revenue figures came in at $4.0 million (Q1 2025), $6.9 million (Q4 2024), and $9.7 million (Q3 2024), per Business Quant data.